NextGen divests automation and software business
This article was originally published in Scrip
Executive Summary
NextGen Sciences, a US-based biomarker service provider, has sold its gene-to-protein automation and software business to eXeTek, a management-led spin-out from the company. The divestment is past of NextGen's plan announced in April to focus all resources on growing its protein biomarker services business. NextGen has acquired a 24% stake in eXeTek, which will be led by former employees Stephen Woodall and Stuart Hill, and will receive 5% royalties on sales for three years. NextGen's protein service portfolio, which it calls biomarker express, includes biomarker discovery and assay development and testing.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.